Marco Siccardi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4090422/publications.pdf

Version: 2024-02-01

127	3,467	117625	182427
papers	citations	34 h-index	51 g-index

131	131	131	3642
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predicting Drugâ€“Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clinical Pharmacokinetics, 2022, 61, 375-386.	3.5	4
2	Drugâ€“Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. Journal of Clinical Pharmacology, 2022, 62, 835-846.	2.0	5
3	PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. Frontiers in Pharmacology, 2022, 13, 814134.	3.5	5
4	A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human. Drug Delivery and Translational Research, 2022, , 1.	5.8	2
5	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. British Journal of Clinical Pharmacology, 2021, 87, 458-470.	2.4	12
6	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drugâ€Drug Interaction Magnitudes in the Elderly. Clinical Pharmacology and Therapeutics, 2021, 109, 471-484.	4.7	10
7	Long-acting drugs and formulations for the treatment and prevention of HIV infection. International Journal of Antimicrobial Agents, 2021, 57, 106220.	2.5	63
8	InÂvitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV Medicine, 2021, 22, 898-906.	2.2	1
9	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R and D, 2021, 21, 9-27.	2.2	31
10	Physiologicallyâ€based pharmacokinetic modeling for dose optimization of the quinineâ€phenobarbital coâ€administration in cerebral malaria patients. CPT: Pharmacometrics and Systems Pharmacology, 2021, 11, 104.	2.5	2
11	Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles. Journal of Materials Chemistry B, 2021, 9, 9874-9884.	5.8	9
12	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics, 2020, 59, 383-401.	3.5	29
13	Physiologicallyâ€Based Pharmacokinetic Modeling for Optimal Dosage Prediction of QuinineÂCoadministered With Ritonavirâ€Boosted Lopinavir. Clinical Pharmacology and Therapeutics, 2020, 107, 1209-1220.	4.7	20
14	Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. Journal of Antimicrobial Chemotherapy, 2020, 75, 640-647.	3.0	15
15	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenetics and Genomics, 2020, 30, 96-106.	1.5	1
16	The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. Journal of Clinical Pharmacology, 2020, 60, S77-S97.	2.0	6
17	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. Journal of Antimicrobial Chemotherapy, 2020, 75, 3417-3424.	3.0	30
18	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	9

#	Article	IF	Citations
19	The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. Journal of Antimicrobial Chemotherapy, 2020, 75, 2381-2383.	3.0	2
20	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 138, 30-36.	4.3	17
21	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 3003-3010.	3.0	13
22	Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 101-109.	4.3	35
23	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. European Journal of Pharmaceutical Sciences, 2019, 140, 105068.	4.0	17
24	Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 2019, 10, 1413.	12.8	34
25	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics, 2019, 20, 217-223.	1.3	4
26	A Comprehensive Framework for Physiologicallyâ€Based Pharmacokinetic Modeling in Matlab. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 444-459.	2.5	32
27	Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. Nanoscale Advances, 2019, 1, 4301-4307.	4.6	5
28	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. Clinical Pharmacokinetics, 2019, 58, 483-501.	3.5	48
29	Predicting Drugâ€“Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. Journal of Infectious Diseases, 2019, 219, 1735-1742.	4.0	40
30	Towards a Maraviroc long-acting injectable nanoformulation. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 138, 92-98.	4.3	20
31	Mechanisms of Drug Interactions II: Transport Proteins. , 2018, , 49-85.		3
32	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
33	Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. Drug Metabolism and Pharmacokinetics, 2018, 33, 179-187.	2.2	11
34	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drugâ€“drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 1004-1012.	3.0	15
35	Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1084, 106-112.	2.3	12
36	In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. Clinical Pharmacokinetics, 2018, 57, 255-266.	3.5	26

#	Article	IF	Citations
37	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. Molecular Pharmaceutics, 2018, 15, 4835-4842.	4.6	42
38	The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 2018, 131, 116-121.	13.7	7
39	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
40	Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-11-30.	0.0	0
41	Development of Prodrug Approaches for Longâ€Acting Nanoformulations of Emtricitabineâ€Based Regimens. FASEB Journal, 2018, 32, 828.3.	0.5	0
42	Use of a physiologically based pharmacokinetic model to simulate drugâ€“drug interactions between antineoplastic and antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw485.	3.0	12
43	Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
44	A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. European Journal of Nanomedicine, 2017, 9, .	0.6	6
45	Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 2017, 9, 1-3.	0.6	1
46	Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. Nanoscale, 2017, 9, 6302-6314.	5.6	32
47	Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. Pharmacology Research and Perspectives, 2017, 5, e00359.	2.4	12
48	Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
49	In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2017, 2, 157-169.	3.6	0
50	Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
51	Physiologically Based Pharmacokinetic Modeling to Predict Drugâ€“Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clinical Pharmacokinetics, 2017, 56, 409-420.	3.5	18
52	Towards a computational prediction of nanoparticle pharmacokinetics and distribution. Journal of in Silico & in Vitro Pharmacology, 2016, 02, .	0.2	4
53	Validation of Computational Approaches for Antiretroviral Dose Optimization. Antimicrobial Agents and Chemotherapy, 2016, 60, 3838-3839.	3.2	2
54	Development and validation of an LCâ€“MS/MS assay for the quantification of efavirenz in different biological matrices. Bioanalysis, 2016, 8, 2125-2134.	1.5	2

#	Article	IF	Citations
55	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. Journal of Interdisciplinary Nanomedicine, 2016, 1, 110-123.	3.6	17
56	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 2016, 7, 13184.	12.8	44
57	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. Journal of Antimicrobial Chemotherapy, 2016, 71, 1041-1045.	3.0	5
58	The Application of Nanotechnology toÂDrug Delivery in Medicine. , 2015, , 173-223.		12
59	Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. Clinical Pharmacokinetics, 2015, 54, 107-116.	3.5	2
60	Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Frontiers in Pharmacology, 2015, 6, 78.	3.5	19
61	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. Journal of Antimicrobial Chemotherapy, 2015, 70, 2816-2822.	3.0	21
62	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clinical Infectious Diseases, 2015, 61, 453-463.	5.8	32
63	Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1203-1217.	3.3	11
64	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Aids, 2015, 29, 193-200.	2.2	13
65	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. Journal of Antimicrobial Chemotherapy, 2015, 70, 555-561.	3.0	35
66	Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2015, 70, 3074-3079.	3.0	11
67	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. Pharmacogenomics, 2015, 16, 919-928.	1.3	14
68	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. Molecular Pharmaceutics, 2015, 12, 3556-3568.	4.6	15
69	Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clinical Pharmacokinetics, 2015, 54, 639-650.	3.5	79
70	Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine, 2015, 10, 1407-1421.	3.3	9
71	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIVâ€infected patients: a population PK approach. Journal of the International AIDS Society, 2014, 17, 19586.	3.0	4
72	CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. Therapeutic Drug Monitoring, 2014, 36, 734-738.	2.0	10

#	Article	IF	Citations
73	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenetics and Genomics, 2014, 24, 459-463.	1.5	21
74	A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 2014, 69, 3275-3281.	3.0	3
75	Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitroâ€“In Vivo Correlation. Advanced Healthcare Materials, 2014, 3, 400-411.	7.6	73
76	Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British Journal of Pharmacology, 2014, 171, 3963-3979.	5.4	91
77	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology, 2013, 1, 4.	3.3	26
78	Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 2013, 52, 583-592.	3.5	47
79	Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. Therapeutic Drug Monitoring, 2013, 35, 78-83.	2.0	35
80	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. Journal of Antimicrobial Chemotherapy, 2013, 68, 907-910.	3.0	21
81	Predicting intestinal absorption of raltegravir using a population-based ADME simulation. Journal of Antimicrobial Chemotherapy, 2013, 68, 1627-1634.	3.0	26
82	Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro. Antimicrobial Agents and Chemotherapy, 2013, 57, 5612-5618.	3.2	26
83	Research Spotlight: Nanomedicines for HIV therapy. Therapeutic Delivery, 2013, 4, 153-156.	2.2	23
84	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology, 2013, 8, 871-890.	1.8	10
85	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. Journal of Antimicrobial Chemotherapy, 2012, 67, 671-674.	3.0	22
86	Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. Therapeutic Drug Monitoring, 2012, 34, 232-235.	2.0	30
87	Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. Therapeutic Drug Monitoring, 2012, 34, 604-606.	2.0	6
88	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. Therapeutic Drug Monitoring, 2012, 34, 722-728.	2.0	31
89	Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 1427-1433.	3.2	32
90	Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. Therapeutic Drug Monitoring, 2012, 34, 165-170.	2.0	37

#	Article	IF	Citations
91	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 2012, 22, 10-19.	1.5	38
92	Efavirenz in an Obese HIV-Infected Patient â€“ a Report and An In Vitroâ€“In Vivo Extrapolation Model Indicate Risk of Underdosing. Antiviral Therapy, 2012, 17, 1381-1384.	1.0	15
93	Determinants of darunavir cerebrospinal fluid concentrations. Aids, 2012, 26, 1529-1533.	2.2	34
94	Divalent Metals and pH Alter Raltegravir Disposition In Vitro. Antimicrobial Agents and Chemotherapy, 2012, 56, 3020-3026.	3.2	52
95	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIVâ€positive patients using dried sample spot devices. British Journal of Clinical Pharmacology, 2012, 74, 134-140.	2.4	30
96	Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy, 2011, 66, 2092-2098.	3.0	93
97	Ceftriaxone bone penetration in patients with septic non-union of the tibia. International Journal of Infectious Diseases, 2011, 15, e415-e421.	3.3	26
98	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antiviral Therapy, 2011, 16, 499-504.	1.0	9
99	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology, 2011, 54, 2279-2279.	7.3	25
100	A HPLCâ€“MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 779-788.	2.8	58
101	Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2011, 66, 1332-1339.	3.0	46
102	Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. Antimicrobial Agents and Chemotherapy, 2011, 55, 2976-2978.	3.2	64
103	Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy, 2011, 55, 879-887.	3.2	58
104	A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. Therapeutic Drug Monitoring, 2010, 32, 86-92.	2.0	20
105	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Aids, 2010, 24, 1064-1066.	2.2	120
106	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Analytical and Bioanalytical Chemistry, 2010, 396, 791-798.	3.7	68
107	Validation of a rapid and sensitive high-performance liquid chromatographyâ€“tandem mass spectrometry (HPLCâ€“MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1455-1465.	2.3	116
108	HPLCâ€“MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 774-780.	2.8	71

#	Article	IF	Citations
109	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenetics and Genomics, 2010, 20, 759-765.	1.5	38
110	Raltegravir Penetration in Seminal Plasma of Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 2744-2745.	3.2	13
111	Population Pharmacokinetic Modeling of the Association between 63396Câ†'T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 2010, 54, 5242-5250.	3.2	66
112	Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma. Antimicrobial Agents and Chemotherapy, 2010, 54, 3408-3413.	3.2	51
113	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. Journal of Antimicrobial Chemotherapy, 2009, 64, 874-875.	3.0	11
114	New HPLCâ€"MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1721-1726.	2.3	98
115	Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV. Therapeutic Drug Monitoring, 2009, 31, 104-109.	2.0	42
116	Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. Clinical Pharmacokinetics, 2008, 47, 793-805.	3.5	36
117	A New Assay Based on Solid-Phase Extraction Procedure with LC-MS to Measure Plasmatic Concentrations of Tenofovir and Emtricitabine in HIV Infected Patients. Journal of Chromatographic Science, 2008, 46, 524-528.	1.4	38
118	Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens. Antimicrobial Agents and Chemotherapy, 2008, 52, 1066-1071.	3.2	17
119	Association of a Singleâ€Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396Câ†'T) with Reduced Concentrations of Unboosted Atazanavir. Clinical Infectious Diseases, 2008, 47, 1222-1225.	5.8	77
120	A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting. Therapeutic Drug Monitoring, 2008, 30, 90-94.	2.0	12
121	An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients. Therapeutic Drug Monitoring, 2008, 30, 662-669.	2.0	105
122	Clinically Significant Drug Interaction between Tipranavir-Ritonavir and Phenobarbital in an HIV-Infected Subject. Clinical Infectious Diseases, 2007, 45, 1654-1655.	5.8	16
123	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 374-378.	2.3	22
124	HPLCâ€"MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 234-240.	2.3	80
125	Unexpected drugâ€"drug interaction between tipranavir/ritonavir and enfuvirtide. Aids, 2006, 20, 1977-1979.	2.2	28
126	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 835, 127-130.	2.3	52

#	Article	IF	Citations
127	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 0, 1, 16.	1.5	11